Novo Nordisk acquires Akero Therapeutics for up to $5.2 billion for access to liver disease drug. Novo to pay Akero shareholders $54 per share upfront with potential additional $6 per share upon full U.S. drug approval. Akero shares surge over 19% in premarket trading. Novo’s CEO announces plan to cut 9,000 jobs and focus on obesity and diabetes drugs. Akero’s efruxifermin being studied for fatty liver disease treatment.

Read more at Yahoo Finance: Novo Nordisk to buy Akero Therapeutics for up to $5.2 billion